Cargando…
Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT
BACKGROUND: Predicting the aggressive behavior of non-functional pancreatic neuroendocrine tumors (NF-PNET) remains controversial. We wanted to explore, in a prospective setting, whether the diagnostic accuracy can be improved by dual-tracer functional imaging (68)Ga-DOTANOC and (18)F-FDG-PET/CT in...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928175/ https://www.ncbi.nlm.nih.gov/pubmed/31872324 http://dx.doi.org/10.1186/s13550-019-0585-7 |
_version_ | 1783482427400781824 |
---|---|
author | Majala, Susanna Seppänen, Hanna Kemppainen, Jukka Sundström, Jari Schalin-Jäntti, Camilla Gullichsen, Risto Schildt, Jukka Mustonen, Harri Vesterinen, Tiina Arola, Johanna Kauhanen, Saila |
author_facet | Majala, Susanna Seppänen, Hanna Kemppainen, Jukka Sundström, Jari Schalin-Jäntti, Camilla Gullichsen, Risto Schildt, Jukka Mustonen, Harri Vesterinen, Tiina Arola, Johanna Kauhanen, Saila |
author_sort | Majala, Susanna |
collection | PubMed |
description | BACKGROUND: Predicting the aggressive behavior of non-functional pancreatic neuroendocrine tumors (NF-PNET) remains controversial. We wanted to explore, in a prospective setting, whether the diagnostic accuracy can be improved by dual-tracer functional imaging (68)Ga-DOTANOC and (18)F-FDG-PET/CT in patients with NF-PNETs. METHODS: Thirty-one patients with NF-PNET (90% asymptomatic) underwent PET-imaging with (18)F-FDG and (68)Ga-DOTANOC, followed by surgery (n = 20), an endoscopic ultrasonography and fine-needle biopsy (n = 2) or follow-up (n = 9). A focal activity on PET/CT greater than the background that could not be identified as physiological activity was considered to indicate tumor tissue. The imaging results were compared to histopathology. The mean follow-up time was 31.3 months. RESULTS: Thirty-one patients presented a total of 53 lesions (40 histologically confirmed) on PET/CT. Thirty patients had a (68)Ga-DOTANOC-positive tumor (sensitivity 97%) and 10 patients had an (18)F-FDG-positive tumor. In addition, one (68)Ga-DOTANOC-negative patient was (18)F-FDG-positive. (18)F-FDG-PET/CT was positive in 19% (3/16) of the G1 tumors, 63% (5/8) of the G2 tumors and 1/1 of the well-differentiated G3 tumor. (68)Ga-DOTANOC-PET/CT was positive in 94% of the G1 tumors, 100% of the G2 tumors and 1/1 of the well-differentiated G3 tumor. Two out of six (33%) of the patients with lymph node metastases (LN+) were (18)F-FDG-positive. The (18)F-FDG-PET/CT correlated with tumor Ki-67 (P = 0.021). Further, the Krenning score correlated with tumor Ki-67 (P = 0.013). (18)F-FDG-positive tumors were significantly larger than the (18)F-FDG-negative tumors (P = 0.012). (18)F-FDG-PET/CT showed a positive predictive value of 78% in the detection of potentially aggressive tumors (G2, G3, or LN + PNETs); the negative predictive value was 69%. CONCLUSIONS: (18)F-FDG-PET/CT is useful to predict tumor grade but not the LN+ of NF-PNETs. Patients with (18)F-FDG-avid NF-PNETs should be referred for surgery. The (68)Ga-DOTANOC-PET/CT also has prognostic value since the Krenning score predicts the histopathological tumor grade. TRIAL REGISTRATION: The study has been registered at ClinicalTrials.gov; Non-functional Pancreatic NET and PET imaging, NCT02621541. |
format | Online Article Text |
id | pubmed-6928175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-69281752020-01-08 Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT Majala, Susanna Seppänen, Hanna Kemppainen, Jukka Sundström, Jari Schalin-Jäntti, Camilla Gullichsen, Risto Schildt, Jukka Mustonen, Harri Vesterinen, Tiina Arola, Johanna Kauhanen, Saila EJNMMI Res Original Research BACKGROUND: Predicting the aggressive behavior of non-functional pancreatic neuroendocrine tumors (NF-PNET) remains controversial. We wanted to explore, in a prospective setting, whether the diagnostic accuracy can be improved by dual-tracer functional imaging (68)Ga-DOTANOC and (18)F-FDG-PET/CT in patients with NF-PNETs. METHODS: Thirty-one patients with NF-PNET (90% asymptomatic) underwent PET-imaging with (18)F-FDG and (68)Ga-DOTANOC, followed by surgery (n = 20), an endoscopic ultrasonography and fine-needle biopsy (n = 2) or follow-up (n = 9). A focal activity on PET/CT greater than the background that could not be identified as physiological activity was considered to indicate tumor tissue. The imaging results were compared to histopathology. The mean follow-up time was 31.3 months. RESULTS: Thirty-one patients presented a total of 53 lesions (40 histologically confirmed) on PET/CT. Thirty patients had a (68)Ga-DOTANOC-positive tumor (sensitivity 97%) and 10 patients had an (18)F-FDG-positive tumor. In addition, one (68)Ga-DOTANOC-negative patient was (18)F-FDG-positive. (18)F-FDG-PET/CT was positive in 19% (3/16) of the G1 tumors, 63% (5/8) of the G2 tumors and 1/1 of the well-differentiated G3 tumor. (68)Ga-DOTANOC-PET/CT was positive in 94% of the G1 tumors, 100% of the G2 tumors and 1/1 of the well-differentiated G3 tumor. Two out of six (33%) of the patients with lymph node metastases (LN+) were (18)F-FDG-positive. The (18)F-FDG-PET/CT correlated with tumor Ki-67 (P = 0.021). Further, the Krenning score correlated with tumor Ki-67 (P = 0.013). (18)F-FDG-positive tumors were significantly larger than the (18)F-FDG-negative tumors (P = 0.012). (18)F-FDG-PET/CT showed a positive predictive value of 78% in the detection of potentially aggressive tumors (G2, G3, or LN + PNETs); the negative predictive value was 69%. CONCLUSIONS: (18)F-FDG-PET/CT is useful to predict tumor grade but not the LN+ of NF-PNETs. Patients with (18)F-FDG-avid NF-PNETs should be referred for surgery. The (68)Ga-DOTANOC-PET/CT also has prognostic value since the Krenning score predicts the histopathological tumor grade. TRIAL REGISTRATION: The study has been registered at ClinicalTrials.gov; Non-functional Pancreatic NET and PET imaging, NCT02621541. Springer Berlin Heidelberg 2019-12-23 /pmc/articles/PMC6928175/ /pubmed/31872324 http://dx.doi.org/10.1186/s13550-019-0585-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Majala, Susanna Seppänen, Hanna Kemppainen, Jukka Sundström, Jari Schalin-Jäntti, Camilla Gullichsen, Risto Schildt, Jukka Mustonen, Harri Vesterinen, Tiina Arola, Johanna Kauhanen, Saila Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT |
title | Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT |
title_full | Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT |
title_fullStr | Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT |
title_full_unstemmed | Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT |
title_short | Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT |
title_sort | prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer pet/ct |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928175/ https://www.ncbi.nlm.nih.gov/pubmed/31872324 http://dx.doi.org/10.1186/s13550-019-0585-7 |
work_keys_str_mv | AT majalasusanna predictionoftheaggressivenessofnonfunctionalpancreaticneuroendocrinetumorsbasedonthedualtracerpetct AT seppanenhanna predictionoftheaggressivenessofnonfunctionalpancreaticneuroendocrinetumorsbasedonthedualtracerpetct AT kemppainenjukka predictionoftheaggressivenessofnonfunctionalpancreaticneuroendocrinetumorsbasedonthedualtracerpetct AT sundstromjari predictionoftheaggressivenessofnonfunctionalpancreaticneuroendocrinetumorsbasedonthedualtracerpetct AT schalinjantticamilla predictionoftheaggressivenessofnonfunctionalpancreaticneuroendocrinetumorsbasedonthedualtracerpetct AT gullichsenristo predictionoftheaggressivenessofnonfunctionalpancreaticneuroendocrinetumorsbasedonthedualtracerpetct AT schildtjukka predictionoftheaggressivenessofnonfunctionalpancreaticneuroendocrinetumorsbasedonthedualtracerpetct AT mustonenharri predictionoftheaggressivenessofnonfunctionalpancreaticneuroendocrinetumorsbasedonthedualtracerpetct AT vesterinentiina predictionoftheaggressivenessofnonfunctionalpancreaticneuroendocrinetumorsbasedonthedualtracerpetct AT arolajohanna predictionoftheaggressivenessofnonfunctionalpancreaticneuroendocrinetumorsbasedonthedualtracerpetct AT kauhanensaila predictionoftheaggressivenessofnonfunctionalpancreaticneuroendocrinetumorsbasedonthedualtracerpetct |